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Nanotechnologies have reached maturity and market penetration that require 
nano-specific changes in legislation and harmonization among legislation 
domains, such as the amendments to REACH for nano materials (NMs) which 
came into force in 2020. Thus, an assessment of the components and regula-
tory boundaries of NMs risk governance is timely, alongside related methods 
and tools, as part of the global efforts to optimise nanosafety and integrate 
it into product design processes, via Safe(r)-by-Design (SbD) concepts. This 
paper provides an overview of the state-of-the-art regarding risk governance 
of NMs and lays out the theoretical basis for the development and implemen-
tation of an effective, trustworthy and transparent risk gover nance framework 
for NMs. The proposed framework enables continuous integration of the 
evolving state of the science, leverages best practice from contiguous disci-
plines and facilitates responsive re-thinking of nanosafety governance to meet 
future needs. To achieve and operationalise such framework, a science-based 
Risk Governance Council (RGC) for NMs is being developed. The framework 
will provide a toolkit for independent NMs’ risk governance and integrates 
needs and views of stakeholders. An extension of this framework to relevant 
advanced materials and emerging technologies is also envisaged, in view of 
future foundations of risk research in Europe and globally.
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The rapid expansion of nanotechnology 
as a key enabling technology (KET) in sev-
eral economic sectors raises significant 
concerns in the scientific and regulatory 
world in many European countries, and 
globally, regarding the possible hazards 
and risks posed by nanomaterials (NMs) 
to human health (both workers and con-
sumers) and the environment,[1] while the 
concerns of the public are highly depend-
able on the risk perception of NMs and 
the level of understanding of nanotech-
nology.[2–5] Such concerns, if not governed 
by proper risk assessment and man-
agement approaches, may significantly 
hamper the great potential of nanotech-
nology to deliver industrial, energy, envi-
ronmental, health, and other benefits.[6] 
In general, the rapid development of 
nanotechnologies has not been matched 
by the speed of nanospecific adjust-
ments in regulatory frameworks for safety 
The ORCID identification number(s) for the author(s) of this article 
can be found under https://doi.org/10.1002/smll.202003303.
© 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, 
Weinheim. This is an open access article under the terms of the Creative 
Commons Attribution License, which permits use, distribution and repro-
duction in any medium, provided the original work is properly cited.
Small 2020, 2003303
www.advancedsciencenews.com www.small-journal.com
2003303 (2 of 12) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
management.[7] NMs are already accepted as vital for new tech-
nologies and innovation, as evidenced by the existence of the 
European Union (EU) Observatory for Nanomaterials[8] and the 
National Nanotechnology Initiative of the USA;[9] however, the 
increasing rate of their utilization seems to outpace regulators 
and researchers in adjusting regulation and research, leaving 
a gap regarding proper handling of NM-related environmental 
and human health risks.[10–12] This consideration of a regulatory 
gap, whether real or perceived, demonstrates a need to reassess 
already adopted NMs, especially those commonly produced and 
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used across a range of applications, as well as emerging innova-
tive NMs, which is where risk governance comes to the fore.[13] 
In order to appropriately manage and support innovation, com-
mercial and regulatory decisions must be clearly guided by a 
broad set of civil society interests and should be supported by 
clear, reliable, relevant, and understandable scientific outputs 
and data, which must also be legally sound and defensible.[14]
Governance systems aim to provide all actors with clarity and 
defined rules to understand what forms of behavior are accept-
able and valid, as well as which actions and behaviors are outside 
the boundaries of established best practices, codes of conduct, 
and overall operating procedures.[15–18] However, since the gov-
ernance concept rose initially, as a tool for evaluating eligibility 
for international development through its use by the Interna-
tional Monetary Fund, World Bank, and other bodies,[19] “what 
‘good governance’ entails” is a persistent debate as best prac-
tices attempt to keep pace with contemporary socio-economic 
developments,[20] especially at the axis of risk and innovation.[21] 
Different forms of governance have varying compositions of 
principles and practices, such as the values and operating prac-
tices of prominent governing bodies of a certain area. These 
principles and practices are informed by trade-offs in risks and 
benefits, or, in other words, governance weighs the potential 
gains and externalities that may be accrued should an activity 
or product be allowed to enter into the public domain or com-
mercial marketplace.[22] The trade-offs are particularly salient 
for technology development and commodification,[23] where 
developers’ economic and scientific incentives must be balanced 
against the potential health hazards and security implications 
posed by a specific technology. This balance is a fundamental 
challenge of risk governance, where the perspectives, incentives, 
and needs of various stakeholders and interest groups inform 
the regulatory requirements and/or informal procedures needed 
for governing the development pathway and commercialization 
of a new technology to enter the marketplace. The international 
risk governance council (IRGC) was first to address the risk gov-
ernance of emerging and systemic risks, as a response to policy 
challenges, and developed a generic framework for risk govern-
ance, which has been considered broadly applicable for nano-
technology as an emerging technology.[24,25]
Despite the significant progress achieved in risk evaluation, 
risk assessment and risk management, of NMs, there is still 
an urgent need to implement a robust and reliable method-
ology for risk governance of NMs via benchmarked decision-
making tools. Within the EU H2020 program, the development 
of a transparent, self-sustained and science based risk govern-
ance council (RGC), through joint efforts from three projects 
(Gov4Nano,[26] NANORIGO,[27] and RiskGONE[28]) has been 
initiated. The RGC development is founded on a clear under-
standing of risks, risk management practices and the societal 
risk perception by all stakeholders to allow the EU member 
states to fully exploit the economic and social potential of NMs 
and nanotechnologies broadly.
2. Governance of Emerging Technologies
Governance of technologies, in more established and better 
understood fields, is largely informed by economic, social, and 
environmental considerations. Technologies in these fields 
often represent an incremental, as opposed to radical, change, 
and therefore many of the mechanisms are likely to have 
already been established, where regulators and other actors 
have kept pace with the development of a given technology. 
Within emerging technologies, corresponding innovation could 
be deemed radical or disruptive, which is often accompanied 
by a set of new and unique governance challenges arising 
from reduced understanding of the health and environmental 
impacts of the new technology. The governance challenges 
posed by NMs, include a range of ethical, social, political, and 
technical issues, such as their dynamic nature, specific physico-
chemical properties (both intrinsic and extrinsic depending on 
context and surroundings), aging, environmental transforma-
tions, behavior, features, and effects.[29–32]
Governance is largely informed by the joint actions of 
risk analysis (including measures of risk prevention, mitiga-
tion, or transfer) and risk communication. Assuming that the 
properties of a technology and technological outcomes are 
well-understood and scientifically testable, such technologies 
and their products are reviewed through characterization and 
assessment of their potential hazards, magnitude of exposure, 
and exposure pathways, i.e., potential exposure of workers or 
consumers, environmental fate, transport, etc. Using various 
tests and benchmarks, the potential hazards of the technology 
and its products are reviewed along their life cycle against 
potential risks, including the magnitude and the frequency 
of occurrence of such risks. Based on such reviews, the tech-
nologies and products are refined and improved to be com-
pliant with formal regulation or less formal “soft laws,” i.e., 
industrial standards and best practices, before entering the 
market.[33] Efforts on risk communication with stakeholders 
and the lay public are commendable to a) inform the public 
regarding the safe use procedures for the given product, 
b) field any potential concerns that may not have been reflected 
in testing, and c) communicate with the public regarding the 
absence of specific risks after rigorous hazard testing and eval-
uation (assuming that this is backed by the experimental data 
acquired).
Emerging technologies pose unique issues to the whole gov-
ernance process, in ways that conventional materials or prod-
ucts generally do not.[17] Notably, emerging technologies like 
nanotechnology might possess unique, uncertain, or incom-
pletely characterized features such as their dynamic evolution. 
Given their emerging nature and current knowledge gaps, 
hazards associated with NMs may be difficult to quantify,[34,35] 
while robust exposure assessment needed for a proper risk 
assessment is still an issue.[36] Particularly, risk analysis of NMs 
suffers from a lack of widely applicable testing strategies and 
assessment benchmarks, which essentially render any risk-
based nanotechnology governance strategy as contested and 
unable to inform safe operating procedures. Uncertainty related 
to physicochemical properties may alter the assessment of haz-
ards and risks even for traditional materials, thus the impact 
of compounding uncertainties for NMs may result in highly 
uncertain and impractical risk estimates.
For example, European Chemicals Agency (ECHA) has 
recently introduced the concept of nanoforms and groups 
of nanoforms that are sufficiently similar as to have the 
same toxicity, however the boundaries of these sets of nano-
forms have yet to be established. Currently, we do not have a 
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clear understanding of whether a 50 nm TiO2 NM with 80:20 
anatase:rutile is the same as a 50  nm TiO2 NM with 75:25 
anatase: rutile in terms of biological effects, nor whether 
a 40  ±  5  nm and a 50  ±  10  nm NM of the same composition 
are sufficiently similar in terms of their uptake and hazard to 
constitute a set of nanoforms.
Without having a clear understanding of the issues described 
above, it is politically and institutionally difficult to craft and 
enforce standards for the broader technology development and 
policymaking communities.[6,37] Existing consensus processes 
to develop and validate agreed standardized testing strategies 
and guidance documents are slow and unwieldy,[14] even where 
strong political will exists, such as the Organization for Eco-
nomic Co-operation and Development (OECD) activities and 
the “Malta Initiative.”[38–41]
Given these difficulties and the lack of a reliable, scien-
tifically based and clear testing strategy for risk assessment of 
NMs, scholars have called for the urgent and timely use of risk 
governance.[6,42,43] The IRGC characterizes risk governance into 





5) Communication of risk within a specific context that is 
influenced by the interactions and preferences of various 
stakeholders.[21]
NMs represent an accumulation of incremental innova-
tions, leading to a larger, more radical step which has driven 
the rapid development and commercialization of certain NMs. 
Despite their prevalence already in the human environment, 
NMs can still be considered an emerging technology (defined 
as a technology reaching their potential within 3–5 years), given 
the insufficient maturity of societal understanding of the risks 
and benefits of NMs and how this understanding is conveyed to 
stakeholders, the radical novelty, rapid growth, variety of poten-
tial NMs composition, and their prominent impacts where 
applied in comparison to the status quo.[44] In short, the full 
impact of NMs is not yet fully understood unlike many larger 
scale chemical equivalents. In the research and development 
phases for NMs there are ranges of governance regimes, at firm 
or institution level, which determine what and how NM innova-
tions are, or are not developed. These more “local” governance 
systems are also influenced by larger systems, such as regional 
or national regulatory frameworks.
Harmonization across regulatory frameworks and domains, 
even within a single country, is challenging. For example, 
US chemical safety regulation (TSCA) allows registration of 
a NM for a specific use (as per drug approvals for a specific 
disease endpoint), while the EU’s chemical legislation, regis-
tration, evaluation, authorization, and restriction of chemicals 
(REACH), requires registrants to consider all possible utili-
zation/exposure scenarios, which therefore establishes firm 
requirements and criteria to be fulfilled before a NM for the 
specified applications can enter the EU market. This places the 
burden upon firms wishing to commercialize NMs to dem-
onstrate the safety of their applications when fulfilling these 
requirements, a burden that may be particularly onerous for 
small businesses. A requirement to consider all use scenarios 
for a new material as a basis for regulation will inevitably leave 
gaps, while also placing a burden on businesses to explore uses 
beyond their targeted markets and applications.
An important challenge for NMs risk governance (and 
indeed commercialization) is that the same NM may have 
multiple different applications, each of which has a completely 
different exposure route, exposure form, exposure potential, 
potential risk, and possibly life cycle. For example, silver-based 
NMs are widely used not only in inkjet printing but also as 
antibacterial agents in wound dressings and medical devices.[45] 
The exposure routes and forms are very different in these cases, 
and, for example, a manufacturer designing a silver NM for 
use in printing would not typically want to generate risk assess-
ments that should be applied for the case of direct contact 
with wounds. Use is intimately connected with the resulting 
exposure route. While exposure has been evaluated less as a 
key criterion for evaluating the risk of NMs[46] it may therefore 
be practical to continue to regulate NMs based on their func-
tional use (therefore exposure), as has been done, to a limited 
extent, for nanosilver in the US, which is regulated under the 
regulations for pesticides. This functional use grouping, would 
bring all materials registered for a given use (nano and non-
nano) together rather than attempting to bring all nano-scale 
materials under a single regulatory umbrella. Such a use-based 
approach could possibly be more efficient but should also be 
framed more by socio-ecological precautionary considerations 
rather than the economically focused process we currently see 
under REACH.
It is worth mentioning that the assessment of realistic expo-
sure levels has also been put in the center of the next genera-
tion risk assessment (NGRA) approach—a step beyond the 
classic risk assessment paradigm. In the classic paradigm, 
the risk measures are calculated by dividing the critical doses 
obtained from animal studies, e.g., NOAEL by some safety 
margins, e.g., a factor of 10 for the extrapolation from the test 
animal to human, plus an additional 10 to account for variability 
within the human population. NGRA is defined as an exposure-
led, hypothesis-driven approach that incorporates one or more 
“New Approach Methodologies” (NAMs, typically alternatives 
to animal testing) to ensure that the chemical does not cause 
harm to consumers. This requires development of integrated, 
tiered and iterative strategies that integrate various types of 
experimental studies, such as high-throughput studies (HTS) 
and omics analyses with computational techniques, such as 
quantitative structure–activity relationships (QSAR), threshold 
of toxicological concern approach (TCC), quantitative in vitro–
in vivo extrapolation (QIVIVE), physiological-based pharmaco-
kinetics modeling (PBPK) and read-across.[47–49]
As mentioned above, the revised Annex VI of REACH[50] 
introduced the concept of nanoform into the regulation, which 
addresses the information requirements concerning nanoscale 
variants of chemical substances, such as NMs. The introduction 
represents an increase in requirements for the authorization 
and possibility to commercialize NMs and products containing 
them. Within the REACH regulation, NMs are considered 
as special forms of a chemical substance, whereas the term 
nanoform is used to distinguish different NMs forms, e.g., 
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different sizes, shapes, or coatings, of the same registered sub-
stance.[51,52] Consequently, each nanoform of a particular sub-
stance must be identified and characterized in the registration 
dossiers. A nanoform must be characterized in accordance with 
Annex VI Section 2.4 of REACH, which states that a substance 
may comprise of one or more different nanoforms, depending 
on the differences in several particle parameters, which always 
have to be considered jointly, i.e., i) size distribution; ii) shape 
and other morphological characterization; iii) surface treatment 
and functionalization; and iv) surface area. Variation in at least 
one of the above parameters will result in a different nanoform, 
unless it is a result of batch-to-batch variability. Since different 
nanoforms of a particular NM may differ significantly in terms 
of their physical, chemical, and/or morphological properties, 
it is expected that different nanoforms of the same substance 
(same NM) may also differ in terms of causing adverse effects 
on human health and/or the environment, and thus require 
separate assessment unless they can be demonstrated to 
constitute a set of nanoforms of similar behavior.
Given the ongoing uncertainty to which physico-chemical 
characteristics of NMs correlate with toxicity,[53,54] a risk gov-
ernance approach has been suggested in order to develop 
collaborative mechanisms across multiple stakeholders and 
institutions to craft and implement the standards, best prac-
tices, and operating culture within the nanotechnology 
industry.[17] Such an approach may benefit from the opera-
tionalization of the Safe(r)-by-Design (SbD) concept that is 
a growing requirement within individual governments, but 
would also stimulate innovation in the international landscape 
of emerging technologies.[55]
The SbD concept aims to establish selection rules and 
synthetic approaches that can be used for the reduction of 
associated risks, while considering the life cycle of products in 
order to protect workers, users and consumers.[56] This can be 
achieved by reducing NMs hazard and/or exposure, reducing 
the migration and/or release of NMs and the controlled deg-
radation once released from their matrices.[31,56] The imple-
mentation of SbD approaches is one of the main elements of 
risk governance of nanotechnology and its incorporation into 
the risk governance framework can enable timely and effective 
high-tech innovation, making NM-products safer for humans 
and the environment, and supporting their acceptance by, and 
value to, customers and society as a whole.[57]
3. Moving from Risk Assessment and 
Management to Governance of Nanomaterials 
and Nanotechnologies
It is well established by most stakeholders in the nanotech-
nology field, i.e., scientific community, regulators/policy 
makers and industry, that traditional risk assessment/risk 
management, although broadly applicable for NMs, demands 
a high level of adaptation and optimization. This is mainly due 
to: i) the special features of NMs, including their aforemen-
tioned applications in a wide array of consumer and indus-
trial applications; ii) their enormous diversity of properties; iii) 
their dynamic nature that responds to/is determined by their 
surroundings (sometimes called extrinsic properties);[31,58,59] 
and iv) the extensive gaps in their characterization under rele-
vant exposure conditions and timescales.[60,61] Primary research 
efforts have so far focused on adjusting risk assessment and 
management frameworks for chemicals to account for the 
properties and characteristics of NMs.
The complexity of the topic and the need for a holistic 
approach have led to the shift in focus from simpler processes 
of risk assessment to risk governance of NMs, seeking more 
relevant rules, validation procedures and regulatory accepted 
processes within risk governance.[14] These processes aim to 
cover the whole innovation process along the life cycle of a 
specific NM, thereby allowing a deeper analysis of foreseeable 
risks that may be posed by NMs, nano-enabled products and 
processes.
Scott-Fordsmand et al.[14] have analyzed the current state of 
the art in the nanosafety sector, by identifying the progress 
of science and regulation in five important sub-sectors, i.e., 
scientific data, nanoinformatics tools, operational tools, gov-
ernance framework, governance council. In the same study, 
the current status and what is missing have been analyzed, 
while a way forward is proposed for each of the sub-sectors, 
followed by a general roadmap and a view into the global per-
spective of nanosafety. A key recommendation from that work 
was the urgent need for the development of a holistic risk gov-
ernance framework, whose aim is to integrate scientific data 
and operational tools, which coupled with guidance and test 
guidelines can lead to the operationalization of a risk govern-
ance council.
Key gaps that have been identified include the ongoing lack 
of: i) consensus in a risk management framework for NMs; ii) 
certified reference materials and positive/negative controls for 
NMs; iii) official test guidelines for characterization and toxicity 
evaluation; iv) methodologies for understanding of the social 
impacts of nanotechnologies; v) consensus strategies for the 
transfer of acceptable risk arising from NMs; and vi) proper 
communication toward stakeholders and society. To address 
these gaps, the RiskGONE consortium envisages a pragmatic 
approach, based on the latest developments in the risk govern-
ance sector, which will be translated into web-based and flex-
ible, yet tailored, guidance schemes to support the governance 
of the risks during the innovation process of NMs.
Inspired by initial discussions on risk governance of nano-
technology in the mid-2000s, scholars are now debating how 
and to what extent it may be developed and implemented within 
various jurisdictions or industries. For example, Hristozov 
et al.[62] have detailed the range of different risk pre-assessment 
and evaluation methods available, Lombi et  al.[63] addressed 
risk governance in the agriculture-nanotechnology field, while 
Grieger et al.[64] have detailed the bevy of tools for risk screening 
of NMs. Similarly, Subramanian et  al.[65] and Isigonis et  al.[66] 
reflected upon tools for nanotechnology risk communication 
and mitigation, Trump et al.[67] presented six options that have 
been deployed to address uncertainty regarding NMs in the 
United States, the European Union, as well as in developing 
countries, while Sørensen et al.[68] evaluated environmental risk 
assessment models for NMs, in relation to their applicability 
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4. Risk Governance Frameworks for Nanomaterials
During the last decade, several attempts have been made to 
create a framework tailored to the risk governance of NMs. 
Notable developments include the nanorisk framework,[69] 
the ISO 31000:2018 Risk Management Framework for new 
technologies,[70] the risk governance framework of IRGC for 
NMs with specific guidelines on governance of emerging 
risks,[71,72] the iNTeg-Risk project Emerging Risk Management 
Framework (ERMF)[73] and the frameworks developed by EU 
funded projects such as NanoTEST,[74] MARINA,[75] SUN,[76] 
NANoReg,[77] NANoReg2,[78] caLIBRAte,[79] and NanoMILE.[80] 
Most of these approaches contain similar elements that form 
the main pillars of risk governance for NMs, such as “risk 
pre-assessment,” “risk concern/safety assessment,” “risk 
evaluation,” “risk management, and decision making,” while 
they are complemented by continuous supporting processes 
such as “risk communication” and “monitoring,” as identi-
fied by Isigonis et  al.[66] The most important characteristics 
of these frameworks have been analyzed in relation to their 
suitability for risk governance of NMs, their advantages and 
disadvantages, their acceptability, legal basis, and broad appli-
cability, enabling identification of knowledge gaps that need to 
be filled, as summarized in Table 1.
A straight-forward methodology has been adopted here for 
assessment of the relevant existing frameworks, by combining 
elements of gap analysis and strengths, weaknesses, opportuni-
ties, and threats (SWOT) analysis. In the first phase, the frame-
works have been analyzed to distinguish their main advantages 
and disadvantages, in terms of their suitability for adoption 
and expansion within a general setting for the risk governance 
of NMs. Advantageous characteristics present in the various 
frameworks have been identified, such as nanospecificity, incor-
poration of SbD elements for NMs, wide applicability, presence 
of guidance, comprehensive applied tools, etc. In addition, the 
most important drawbacks of each effort have also been identi-
fied, such as the lack of guidance, lack of nanospecificity and 
applicability in comprehensive tools, the (over)simplicity of 
some frameworks, the focus on a limited set of risk govern-
ance processes, etc. The second phase of analysis focused on 
identifying the level of data intensity that is required for the 
application of each framework (e.g., qualitative vs quantitative 
assessments, low/medium/high data intensity) and specific 
characteristics related to the stakeholder acceptance, in terms of 
regulatory compliance, and the applicability of the frameworks 
in low and middle income countries. It is worth noting at this 
stage that none of the proposed frameworks has complete regu-
latory acceptance/adoption so far, which together with the legal 
basis are two rather important characteristics in the effort to 
establish frameworks and standards suitable for risk govern-
ance of NMs overall. The last phase of the analysis performed 
herein considered possible improvements and steps that would 
allow widespread acceptability and possible utility of each ana-
lyzed framework for the RGC. This step identified a number of 
options such as expansion to cover a larger number of risk gov-
ernance processes, integration in web tools or decision support 
systems, provision of extensive guidance, and others. All in all, 
this analysis allowed extraction of the important characteristics 
from each framework for further utilization within the design 
of the risk governance framework that is being developed by 
the RiskGONE consortium.
The proposed framework aims to incorporate valuable 
existing information and the new developments into one struc-
ture that will be the basis for the operationalization of the RGC. 
The existing risk governance frameworks have specific draw-
backs, as analyzed and summarized in Table  1, and include 
fragmented resources based on the background and the scope 
of their development, therefore it is considered sensible to col-
lect all the important elements under one umbrella, i.e., within 
the envisioned holistic risk governance framework.
To support innovation, a strong focus of recent research has 
been driven toward establishing procedures that would allow 
the integration of SbD concept into NMs development and 
commercialization at the outset, therefore aiming to couple the 
risk governance processes with regulatory and business needs 
and embedding risk governance concepts into the underlying 
frameworks.[57,81–83]
The integration of SbD together with concepts of “Quality-
by-Design” and “Sustainability-by-Design” for NMs has been 
envisioned in related frameworks.[84,85] To achieve such an 
operationalization of SbD and related concepts, scientific and 
regulatory needs are mapped in parallel with innovation man-
agement needs that together with prevention-based and safer-
innovation approaches have to be incorporated within the 
emerging risk governance frameworks. Achievement of such a 
holistic, operational, and transparent framework, acceptable to 
and trusted by all stakeholders is the ultimate goal of risk gov-
ernance research.
Despite the undoubted progress in the field, consensus 
on the safe development and handling of nanotechnology 
among the various stakeholder groups is still considered as 
a great challenge.[86] Therefore, the dedicated RGC for NMs, 
under development by three H2020-funded research projects 
(Gov4Nano,[26] NANORIGO,[27] and RiskGONE[28]), aims to 
support the translation of research advances into regulation 
and industrial practice, and to integrate research, develop-
ment and innovation (R&D&I) processes in nanotechnology 
in a holistic way. These projects aim to design and implement 
a broadly accepted among stakeholders, scientifically based 
risk governance framework for NMs by filling identified gaps 
of the existing efforts[14] (see Table 1 above for some of the key 
information gaps identified in terms of broad applicability, 
stakeholder acceptability, and legal basis). Furthermore, the 
projects aim to support the framework through a dedicated 
web platform and allow modular expansion possibilities to 
accommodate the future needs of NMs industries, regulators 
and the general public. This approach is expected to enable a 
continuous incorporation of the evolving state of the science to 
facilitates responsive re-thinking of nanosafety governance to 
address these future needs. In addition, in close cooperation 
with all consortia, three H2020-funded research projects (Nano-
Commons,[87] NanoInformaTIX,[88] and NanoSolveIT[89]) are 
developing models which can make predictions based on prior 
experimental inputs, utilizing only knowledge of NM structure 
and composition, enabling NMs developers to screen NMs in 
silico before actually producing them, thus ensuring that the 
properties of concern are reduced or eliminated, which would 
make the NMs SbD.[90]
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Table 1. Characteristics of risk governance frameworks developed or adapted for NMs during the last decade.
Framework Advantages Limitations Data needs Stakeholder 
acceptance
Applicability to third 
countries





Nanospecificity. Result of 
industry-NGO dialog, practical, 
transparent and flexible
Not widely accepted 
among NGO com-
munity, simplistic under 
conditions
Qualitative and 
normative, data are 
not handled
Unknown Not country-specific Update and expansion





normative, data are 
not handled
Partial Global Nanospecificity
IRGC Introduced by neutral party with 
good reputation, widely known. 
Wide applicability
Not nanospecific, 
generic risk governance 
concept, no legal status 
of the organization, not 
applied in a comprehen-
sive tool
Qualitative and 
normative, data are 
not handled
Partial Not country-specific Nanospecificity, integration in a 
comprehensive online web-tool as 
a decision supporting system
iNTeg-Risk ERMF Nanospecificity. Expansion of 
emerging risk management 
framework to NMs, elaboration of 
IRGC framework
Not applied in a com-
prehensive tool
Qualitative and nor-
mative, data are not 
handled
Unknown EU-centric Expansion to cover all stages of 
risk governance, integration in a 
comprehensive online web-tool
NanoTEST Nanospecificity. Development of 
tools. Testing strategy (in vitro, 
in silico) and high throughput 
methods
Limited to hazard and 
risk assessment
High Partial Not country-specific Integration in a comprehensive 
online web-tool as a decision sup-
porting system for risk governance 
of NMs
MARINA Nanospecificity. First genera-
tion, nanospecific and applied 
framework
Focus only on risk 
assessment strategies 
and risk management 
toolbox
High Unknown EU-centric Expansion to cover all stages of 
risk governance, integration in a 
comprehensive online web-tool
SUN Nanospecificity. Covers regulatory 
risk assessment functionalities. 
Framework supported by modular 
decision support system, online 
access. Tiered approach, tested
Data intensive Tier 1: limited, Tier 
2: high
Partial EU-centric, possibly 
extendable
Expansion to integrate further 
modules, include guidance
NANoREG 1 Nanospecificity. Applicability 
of EU regulatory frameworks 
to NMs, practical guidance for 
regulatory and industry bodies. 
Covers strategies for REACH 
implementation. Supported by 
NANoREG Toolbox
Not applied in a com-
prehensive tool
Medium Partial EU-centric (adapts 
REACH), possibly 
extendable
Integration in a comprehensive 
online web-tool as a decision sup-
porting system for risk governance 
of NMs, including examples of 
case studies and user-friendly 
search system for basic user 
queries
NANoREG 2 Nanospecificity. Defines SbD con-
cept for NMs. Covers grouping 
concepts within regulatory 
frameworks.
Provides new approaches of 
grouping NMs. Safe innovation 
approach
Not applied in a com-
prehensive tool
Medium Partial EU-centric, possibly 
extendable
Integration in a comprehensive 
online web-tool as a decision sup-
porting system for risk governance 
of NMs, including examples of 
case studies and user-friendly 
search system for basic user 
queries
caLIBRAte Nanospecificity. Supported by the 
nanorisk governance portal, busi-
ness innovation centric, elabora-
tion of ERMF framework
Not applied in a com-
prehensive tool
High, depending on 
tool selection
Unknown EU-centric, possibly 
extendable
Integration in a comprehensive 





models, risk assessment tools 
for the virtual screening of 
NMs through the Enalos cloud 
platform
Lacking guidance, life 
cycle considerations
High Unknown Non country specific Available as a cloud platform and 
integrated as a tool in the Nano-
Commons research infrastructure; 
will be packaged as standalone 
software, more case studies to 
be included, range of NMs and 
endpoints extended in NanoCom-
mons and NanoSolveIT projects
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As more experimental data become available, these models 
can be retrained to be more robust and extend their domain of 
applicability to gain more insight into the features driving NMs 
functionalities or adverse effects.
5. A Scientific View on a Universal Risk Governance 
Framework and Plans for Development and 
Operationalization of a Risk Governance Council
Responsible and sustainable nanotechnology innovation 
requires the development and implementation of widely agreed 
strategies and tools for prevention, assessment, communica-
tion, and management of risks and impacts, across materials 
and product life cycles. It should also reflect contiguous con-
cerns, such as the circular economy, critical raw materials, the 
water and waste framework directives,[91,92] and guidance in 
food and feed chains,[93] ultimately leading to the development 
of a holistic risk governance framework for nanotechnologies 
and NMs.[14] Within the RiskGONE project, a modular risk gov-
ernance framework is envisioned, based on the state-of-the-art 
in the nanotechnology sector, the incorporation of risk/benefit 
ratio and ethical assessments[94] and the efforts to couple the 
notions of life cycle thinking, prevention-based risk governance, 
SbD, safe innovation governance, contiguous frameworks, and 
open data initiatives with the existing four main pillars of the 
risk governance process, as shown in Figure 1.
The principal components of risk governance frameworks, 
such as risk pre-assessment, risk appraisal, risk evaluation, and 
Figure 1. Schematic illustration of the holistic and implementable RiskGONE universal nanotechnologies risk governance framework.
Small 2020, 2003303
www.advancedsciencenews.com www.small-journal.com
2003303 (9 of 12) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
risk management have been described extensively in various 
previous studies.[66,71] They are accepted by the scientific com-
munity as important steps in chemical and material assess-
ment and are used in the most recent research regarding risk 
governance processes for NMs. Our study uses the pre-existing 
principal components as the basis of the envisioned risk gov-
ernance framework and focuses on the development and incor-
poration of specific elements that are currently missing and are 
considered essential toward the establishment of science-based 
risk governance of NMs, as also seen in Table 1. These elements 
include the following:
1) Promotion of the incorporation of the SbD concept, alongside 
the sustainability by design and quality by design concepts, 
within assessment frameworks and their operationalization 
through comprehensive tools, which are currently in their 
infancy or missing completely. This effort is meant both to 
help innovation governance, to support responsible research 
and innovation (RRI) with practical and operational tools and 
to enhance predictive actions and measures covering the life 
cycle of NMs or even precede their realization via in silico 
screening.
2) Communication among stakeholders through bi-directional 
communication tools; a web-based platform which will allow 
the public to communicate with stakeholders and vice versa, 
in an effort to facilitate dialog and explore public and societal 
objectives.
3) Guidance and standardization documents, for enhancing 
the regulatory compliance and acceptance of the developed 
framework and the incorporated tools.
4) Strengthening of the scientific efforts toward open data and 
global data availability, through the development of open 
databases and repositories supporting findable, accessible, 
interoperable, and reusable (FAIR) data and promoting the 
FAIRification processes.
5) Utilization of risk governance tools (both existing and those 
to be developed) and incorporation of decision trees that will 
guide the users (covering regulators, industry and the public) 
in the use of the cloud platform (thus the applied framework) 
and the redirection to available resources for the needs of 
each stakeholder group. Resources will include guidance 
documents, standardization documents, public summaries, 
internet resources (databases, information portals), commu-
nication tools and scientific tools.
The risk governance council is at the epicenter of all the 
developments of the RiskGONE project, therefore closely 
related to the development of the risk governance framework 
and the associated supporting infrastructure, i.e., data, tools and 
instruments, which is expected to be developed until the end 
of project timeframe. The RGC is expected to undertake 
and optimize multiple stakeholder involvement activities 
through the bidirectional communication channel that is under 
development.
The risk governance frameworks developed so far have not 
been designed with exclusive consideration of how they would 
be operationalized, i.e., outlining how the framework would 
support the work of a science-based, regulatory, sustainable 
RGC, that would be able to provide expert opinions on the 
ongoing developments in risk related issues for NMs tailored 
to the needs of regulators, industry, society, and other stake-
holders. The foundation of the RGC’s activities, based on the 
RiskGONE consortium vision, should be based on various key 
steps for creating a strong formal framework: i) using FAIR[95] 
scientific data; ii) making use of OECD/EURL ECVAM (Euro-
pean Union Reference Laboratory for alternatives to animal 
testing/European Centre for the Validation of Alternative 
Methods) validated datasets and nanoinformatics tools; iii) ena-
bling the operationality of the tools for aligning the risk gov-
ernance practices through accessible cloud platforms; and iv) 
aligning with open data initiatives and supporting the valida-
tion processes for data and models.
The vision is thus to design a framework for supporting the 
RGC activities through the early adoption of scientific advances 
and emerging data and their translation via functional tools, all 
within a transparent, guided decision scheme considering the 
needs and expectations of the various stakeholders. The risk 
governance framework will be available as an interoperable 
cloud platform with a user-friendly interface and operationalized 
via a set of decision trees implemented into a modular decision 
support tool providing instruments, guidance and guidelines for 
different aspects of the risk governance of NMs, such as:
1) Characterization, fate, and dosimetry of NMs
2) Human hazard assessment
3) Environmental hazard/effect assessment
4) Exposure assessment
5) Human health risk assessment
6) Ecological risk assessment
7) Environmental impact assessment and life cycle analysis





13) Ethical impact assessment
Tools are expected to be categorized based on their suitability 
for use in the different risk governance processes and their 
reliability to support them. Specific assessment has been done 
in previous projects, such as within the H2020 caLIBRAte[79] 
project where the evaluation of the relevance of tools for 
horizon scanning, environmental risk assessment and human 
health risk assessment has been performed. These results will 
be complemented with new tools, especially those developed 
within the NanoSolveIT, NanoCommons, and NanoInformaTIX 
nanoinformatics projects.[87–89] Multiple tools covering the mul-
tiple stages of risk governance processes therefore they are 
expected to be proposed to the users in the various modular yet 
integrated segments of the decision trees that will be used to 
guide the users to appropriate resources.[66]
The specific system requirements and specifications are 
currently being defined in collaboration with the Nano-
SolveIT project.[96] Concrete exploitation and sustainability 
plans are also foreseen and are currently under development 
to ensure continuity, beyond the specific project duration. Key 
aspects of the cloud platform include the utilization of open 
access approaches where feasible, recognition of the need for 
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data security, the need for easily extendable and adaptable 
approaches to keep pace with knowledge and technological 
development, and its hand-over to the RGC, in any of the pos-
sible forms it might take, as part of the long term operationali-
zation. Project partners commit to keeping the cloud platform 
functional for at least 5 years beyond the project lifetime in the 
absence of its uptake and onward development by the RGC.
The decision trees will be designed and implemented, to 
provide scientific and regulatory support via reinforced deci-
sion-making tools and facilitated risk communication to rel-
evant stakeholders, including industry, regulators, insurance 
companies, NGOs, and the general public. The decision trees 
will be complemented by relevant toolboxes and guidance mate-
rials, to support the RGC in the risk governance processes. The 
required, critical properties of nanoforms would be predicted 
(calculated) with the implemented nanoinformatics tools that 
are currently under development by the collaborating projects 
(NanoSolveIT, NanoCommons, and NanoInformaTIX). The 
framework is expected to support regulatory decision-making 
as well as business management needs, through the adoption 
of best practices, the promotion of RRI[97–99] and the exploration 
of frameworks for responsible innovation[100] for integration 
with the proposed risk governance framework to align policy-
making with research practices. Extension to other relevant 
advanced materials and emerging technologies is also envis-
aged along with leveraging of best practice from contiguous 
disciplines.
In some respects, the results of almost 20 years of risk 
research have shown that health hazards from respirable, bio-
resistant dusts in particle and fibrous form are not limited to 
diameters below 100 nm, but also affect other (advanced) mate-
rials that do not fall under the definition of a “nanoform.”[101–103]  
Recent debates consider NMs as new materials generally, 
where the nanoscale is one feature, but not the only one. To 
address the size issue, it is indicated that particulate behavior, 
irrespective of whether engineered or incidental, is clearly cor-
related with disease outcomes in specific cases.[104] Even though 
understanding the subtleties of these features, especially their 
potent combinations, is advancing, further research is needed. 
A library of NMs has been recently published,[105] which con-
tains information that is clearly above what can be measured 
case-by-case and would allow determination of groups of nano-
forms, once appropriate models are developed and validated for 
regulatory use. However, specific investment through govern-
ance/stakeholder dialog is needed to determine the appropriate 
endpoints for screening needs. In this context, while limited 
acute effects at relevant exposure levels have been observed, very 
little is still known about chronic and multi-generational effects. 
Thus, significant research investment is still needed to address 
these aspects of NMs safety and support revision of test guide-
lines for NMs.[106,107] A long-term aim of the risk governance 
council must thus include continuous monitoring, investiga-
tion and understanding of NMs behavior and risks, i.e.,—in 
one word, governance. This issue contributes to the change of 
focus in the next EU research framework program “Horizon 
Europe,” where the corresponding funding for risk research is 
anchored under the generic term “advanced materials.” Consid-
erable uncertainty still exists, thus making NMs an example of 
the diversity and complexity of advanced materials.
The operationalization of the risk governance framework 
remains a great challenge, as previous efforts were mainly con-
ceptual, lacked regulatory acceptance and were barely used for 
decision making, or to support solving practical problems or 
clarification of concerns and uncertainties in the nanosafety 
sector. Now driven directly by regulators, the establishment 
of a risk governance body for NMs will enable the RGC to 
make developed tools operational and to provide communica-
tion with stakeholders and civil society, based on high quality 
information, by reviewing scientific and regulatory data to 
provide science-based, justified opinions regarding the envi-
ronment and human health safety of NMs applied in different 
products and sectors. The following characteristics are consid-
ered vital for establishing the functionality of the RGC and its 
development should ensure:
1) Financial stability/sustainability
2) Neutral/independent status and reputation
3) Transparent and science-based procedures and advice
4) Strong and diverse stakeholder engagement and 
involvement
6. Conclusion
The challenge posed in the nanotechnology sector is the devel-
opment of a universally accepted framework, which is able 
to meet the risk and innovation governance challenges that 
are known at the moment, while at the same time is flexible 
enough to accommodate the envisioned needs of nanotech-
nology and advanced materials as an emerging technology. 
Operationalization and obtaining regulatory acceptance of 
the framework remain key open questions, which should be 
tackled in parallel with its development, while tackling the 
uncertainty and diversity/complexity of NMs is considered 
also a top priority. Consensus is vital for the success of the 
RGC and thus strong focus is needed to perform effective 
collaboration among the three risk governance (Gov4Nano, 
NanoRIGO, and RiskGONE) and the three nanoinformatics 
projects (NanoCommons, NanoSolveIT, and NanoInfor-
maTIX), that are developing the models and predictive tools 
that the RGC will use once established. Such collaboration 
and coordination of efforts, should consider existing methods, 
together with cross-validation of new models/modeling 
approaches, including their predictive power and applica-
bility domains, to enable achievement of the collective goal 
of reaching unprecedented standards of excellence in the risk 
governance of NMs.
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